IMP Welcomes FDA Approval of First-Ever Treatment for TK2d
IMP Welcomes FDA Approval of First-Ever Treatment for TK2d International Mito Patient (IMP) is delighted to welcome yesterday’s approval by […]
IMP Announces New Board Following Election
IMP is delighted to announce the results of its recent Board elections, confirming a dynamic and diverse leadership team that
Scientists provide first evidence that the drug sildenafil may benefit patients with Leigh syndrome, and particularly those carrying mutations in the mitochondrial gene MT-ATP6.
Primary Mitochondrial Myopathies: Patient Journey
Navigating the journey to gain a diagnosis of Primary Mitochondrial Myopathy can be unnecessarily long, intensely stressful, and fraught with obstacles.
Countdown to Rare Disease Day 2025!
The countdown is on to Rare Disease Day 2025 which takes place on 28 February.
Collaboration with MITGEST
IMP is proud to support MITGEST. This international consortium brings together world-class academic experts in mitochondrial research.
SIMPATHIC project prepares to launch clinical trial
The SIMPATHIC project is preparing to launch a clinical trial using Sildenafil as a potential treatment for Leigh syndrome.
IMP joins UK MitoCohort Oversight Committee
IMP are delighted to have been asked to join the UK MitoCohort Oversight Committee. The UK Mitocohort is a UK wide database that collects clinical information on patients living with mito, to help advance understanding of the disease.
The PolG Foundation: Advancing Research and Hope for POLG Disorders
The PolG Foundation is committed to accelerating research efforts to develop effective treatments and, ultimately, a cure for POLG mitochondrial disorders.
LHON Awareness Day Webinar
During this year’s World Mitochondrial Disease Week, IMP hosted a free webinar on 19 September for LHON Awareness Day. The theme for the webinar was LHON and Gene Therapy: Where are they now?